Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
AI
A1 A2 A3
KVUE
FY2025 Q2
Lowered
Kenvue Inc. earnings call
Buzzberg read
Revised 2025 guidance to low single-digit organic sales decline
Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05.
Buzzberg read Revised 2025 guidance to low single-digit organic sales decline Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05. Read full analysisCollapse analysis
Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05.
- Reported Q2 2025 organic sales declined 4.2% year-over-year, massively underperforming consumption growth, driven by retailer inventory destocking.
- Identified a 83% of US self-care business held or gained share, with Tylenol and Zyrtec as bright spots despite weak seasons.
- Admitted to self-induced complexity with 115 brands and a long tail of SKUs accounting for ~1% of sales.
Revenue$3.839B+3% QoQ
EPS$0.29+21% QoQ
Gross margin58.9%Reported
Operating margin18.03%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Strategy
Plan to reduce complexity by trimming SKU tail
Leadership
New leaders appointed to one-third of leadership team
Show 3 more callouts
Strategy
Strategic review of alternatives underway with board committee
Costs
Tariffs expected to have $150 million annualized impact
Performance
Q2 organic sales declined 4.2%, below expectations
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $3.839B | +3% QoQ |
| EPS | $0.29 | +21% QoQ |
| Gross margin | 58.9% | Reported |
| Operating margin | 18.03% | Reported |
| Free cash flow | $0.533B | Reported |
| Capex | $0.088B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2025 | $1.00–$1.05 | $1.02 | Lowered |
| Revenue | FY2025 | -3%–-1% | -2% | Lowered |
AI, capex & demand read
Management read
Cautiously Determine
Management acknowledged weak results and challenges, but expressed confidence in executing a turnaround through focused priorities and leadership changes.
Management AI read
Management emphasized leveraging data and AI capabilities as part of a modern CPG playbook, and announced a new Chief Technology and Data Officer to accelerate digital and AI capabilities.
all 5 named companies below
Companiesreturns since call
Supply chain
Supply chain
Amit Banati
Kenvue's massive underperformance versus consumption (4.2% sales decline vs. positive consumption) implies retailers are aggressively destocking, which will pressure their wholesale partners' near-term revenue visibility. — The consumption-to-shipment gap indicates a channel-wide inventory correction, which could signal a temporary headwind for competitors relying on shipments to retailers for their own reported sales.
Evidence
“global consumption grew year over year and outpaced organic sales across each segment.”
Supply chain
Kirk Perry
Despite a record-weak US allergy season, Zyrtec gained household penetration and share. This points to share gains coming from competitors, not category growth, putting pressure on rival allergy brands. — Zyrtec's share and penetration gains during a weak tide indicate it is taking share from competitors, signaling a negative trend for competing allergy franchises in the US.
Evidence
“Zyrtec didn't just strengthen its leadership position, but also grew household penetration across both adult and children franchises.”
Supply chain
Amit Banati
Kenvue explicitly stated it is losing share in mouthwash because it is not playing strongly enough in the fastest-growing mild alcohol-free segment, a direct signal to competitors with strong offerings in that segment. — This admission provides a clear roadmap for competitors to double down on the alcohol-free oral care segment to entrench their share gains against Listerine.
Evidence
“The key challenge our teams are addressing is on our portfolio mix where we are not playing strongly enough in the fastest growing mild alcohol free segment.”
External signals
Supply-chain alpha · 3returns since call
Kenvue's massive underperformance versus consumption (4.2% sales decline vs. positive consumption) implies retailers are aggressively destocking, which will pressure their wholesale partners' near-term revenue visibility.
Despite a record-weak US allergy season, Zyrtec gained household penetration and share. This points to share gains coming from competitors, not category growth, putting pressure on rival allergy brands.
Kenvue explicitly stated it is losing share in mouthwash because it is not playing strongly enough in the fastest-growing mild alcohol-free segment, a direct signal to competitors with strong offerings in that segment.
Methodology & coverage
Management-only analysis. All 5 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.